an immortalized human salivary acinar cell line were incubated with 100 M EGCG (a physiologically achievable level for topical application or oral administration) for various time periods and then analyzed by cDNA microarray analysis, reverse transcription-polymerase chain reaction, and Western blotting for expression of several major autoantigen candidates. EGCG inhibited the transcription and translation of major autoantigens, including SS-B/La, SS-A/Ro, coilin, DNA topoisomerase I, and ␣-fodrin. These findings, taken together with green tea's anti-inflammatory and antiapoptotic effects, suggest that green tea polyphenols could serve as an important component in novel approaches to combat autoimmune disorders in humans.
Autoimmune disorders are a significant clinical problem; their prevalence in the United States is estimated at more than 8.5 million (Jacobson et al., 1997) . They are often associated with serious morbidity and, in some cases, lead to death. The pathogenesis of most autoimmune disorders, including systemic lupus erythematosus (SLE) and Sjö-gren's syndrome (SS), remains incompletely understood (Yamamoto, 2003; Venables, 2004) . SLE and SS are characterized by the production of autoantibodies against normal cellular components, designated as autoantigens, that may be overexpressed (Gerl et al., 2005) . The production of autoantibodies is considered to be a key mechanism of pathogenesis. To date, a large number of autoantigens have been identified in SLE (Sawalha et al., 2003) . Sera from lupus patients often have high titers of antinuclear autoantibodies (ANA) that target components of the nucleus (Sawalha and Harley, 2004) . These ANA include SS-A/Ro, SS-B/La, centro-mere proteins (CENP) A, B, and C, double-stranded DNA, polymyositis-scleroderma, RNA polymerases, poly(ADP)-ribose polymerase (PARP), uridine-rich 1 small nuclear ribonucleoprotein (RNP), Smith antigen, ribosomal-P, histidyltRNA synthase (Jo-1), and DNA topoisomerase I (Scl-70) (Reeves, 2004) . ANA are also found in approximately 70% of patients with SS, and autoantibodies against SS-A/Ro and SS-B/La are found in approximately 95 and 87% of primary SS patients, respectively (Rehman, 2003) . Elevated levels of SS-A/Ro and SS-B/La mRNA were found in the salivary tissues of SS patients with xerostomia (Bolstad et al., 2003) . Lupus-associated autoantigens also include golgins present in the Golgi apparatus and coilin proteins (Stinton et al., 2004) .
Treatment options for most autoimmune disorders are limited and, in general, seek to suppress the immune response. In contrast, Chinese traditional medicines composed mostly of herbal extracts or green tea contain naturally occurring materials that may provide sources of alternative remedies for autoimmune disorders. Previous studies in animal models suggested that green tea polyphenols (GTPP) are able to reduce inflammation and apoptosis associated with autoimmune activities. In a mouse model for rheumatoid arthritis, 0.2% GTPP in water significantly reduced the protein levels of cyclooxygenase-2, interferon-␥, TNF-␣, and IgG in the joints, resulting in Ͼ50% reduction of collagen-induced arthritis (Haqqi et al., 1999) . In a mouse model for autoimmune encephalomyelitis, oral administration of EGCG reduced clinical severity by reducing brain inflammation and neuronal damage, paralleling diminished proliferation and TNF-␣ production in encephalitogenic T cells (Aktas et al., 2004) . In an SLE mouse model, MRL/MpJ-Fas lprcg /Fas lprcg (MRLlpr cg ) mice fed a 2% green tea powder diet for 3 months had prolonged survival with reduced lymph node hyperplasia and anti-DNA antibody levels, raising the possibility that GTPP could inhibit the expression of autoantigens (Sayama et al., 2003) .
Herein, we report the novel finding that GTPP at physiologically achievable levels down-regulates the expression of several major autoantigens in both normal human epidermal keratinocytes (NHEK) and normal human salivary acinar cells. This finding is relevant for studies using GTPP as a treatment component of autoimmune disorders.
Materials and Methods
Chemicals and Antibodies. EGCG (molecular formula: C 22 H 18 O 11 , purity, Ͼ95%) was purchased from Sigma-Aldrich (St. Louis, MO). Anti-human CENP-C (H-300) rabbit polyclonal antibody, anti-human 52-kDa Ro/SSA (D-12) mouse monoclonal antibody, anti-human PARP (F-2) mouse monoclonal antibody, and anti-human actin (I-19) goat polyclonal antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-human coilin mouse monoclonal antibody was obtained from BD Biosciences Transduction Laboratories (Lexington, KY). The anti-human golgin-67 rabbit polyclonal antibody was a kind gift from Dr. Don Fujita (University of Calgary, Calgary, Canada). The anti-human La/SSB mouse monoclonal antibody was purchased from ImmunoVision (Springdale, AZ).
Cell Lines. NHEK were purchased from Cambrex Bio Science Baltimore, Inc. (Baltimore, MD) and subcultured in keratinocyte growth medium-2 provided by the manufacturer. Subculture of the NHEK was performed by detaching the cells in 0.25% trypsin and transferring into new tissue culture flasks. The immortalized human salivary gland acinar cells (NS-SV-AC) have been described previously (Azuma et al., 1993) . These cells were selected after transfection of origin-defective SV40 mutant DNA and maintained in keratinocyte growth medium-2; they were kindly provided by Dr. Masayuki Azuma (Tokushima University School of Dentistry, Tokushima, Japan). The human oral squamous cell carcinoma line OSC2 was described previously (Osaki et al., 1994) . The cells were cultured in Dulbecco's modified Eagle's medium/Ham's F-12 50/50 MIX medium (Cellgro, Kansas City, MO) supplemented with 10% (v/v) fetal bovine serum, 100 IU/ml penicillin, 100 g/ml streptomycin, and 5 g/ml hydrocortisone.
Cell Treatment. EGCG was dissolved in cell culture media as a 5 M stock immediately before use. Exponentially growing cells were incubated with 100 M EGCG for various time periods (0, 0.5, 2, 6, 24, and 48 h) in the growth media described above, and then they were extracted for total RNA or protein before gene array analyses, RT-PCR, or Western blots.
Affymetrix Gene Array Analyses. Total RNA was isolated from the control and EGCG-treated NHEK cells using silica gel membranes and further purified using spin columns (QIAGEN, Valencia, CA). The quantity of the RNA was estimated with an RNA quantification kit (RiboGreen; Invitrogen, Carlsbad, CA), and samples were stored at Ϫ70°C.
Samples (10 g) of total RNA were used to make ds-cDNA using the SuperScript Choice System (Invitrogen) with an oligo(dT) primer containing a T7 RNA polymerase promoter (Genset, San Diego, CA). After second-strand synthesis, the reaction mixture was extracted with phenol-chloroform-isoamyl alcohol (25:24:1) and ds-cDNA was recovered by ethanol precipitation. Biotin-labeled cRNA was then produced from the ds-cDNA by in vitro transcription using the Enzo RNA transcript labeling kit (Enzo Life Sci, Farmingdale, NY). The cRNA was purified using an RNeasy affinity column (QIAGEN) and fragmented randomly to sizes ranging from 35 to 200 bases by incubating with fragmentation buffer (40 mM Tris acetate, pH 8.1, 10 mM KOAc, and 30 mM MgOAc) for 35 min at 94°C. The hybridization solutions contained 100 mM MES, 1 M Na ϩ , 20 mM EDTA, and 0.01% Tween 20. The final concentration of fragmented cRNA was 0.05 g/l in the hybridization solution. Targets for hybridization were prepared by combining 40 l of fragmented transcripts with sonicated herring sperm DNA (0.1 mg/ml), bovine serum albumin, and 5 nM control oligonucleotide (Affymetrix, Santa Clara, CA) in a buffer containing 1.0 M NaCl, 10 mM Tris-HCl (pH 7.6), and 0.005% Triton X-100. Target cRNA was hybridized for 16 h at 45°C to a set of human oligonucleotide arrays (HuG133A; Affymetrix), which contained 22,283 genes. Arrays were then washed at 50°C with stringent solution (100 mM MES, 0.1 M (Na ϩ ), and 0.01% Tween 20) and then at 30°C with nonstringent washes [6ϫ saline/sodium phosphate/EDTA (0.18 M NaCl, 0.01 M sodium phosphate, pH 7.7, and 1 mM EDTA) and 0.01% Tween 20]. Arrays were then stained with streptavidin-phycoerythrin (Invitrogen). DNA chips were read with a GeneArray Scanner (Hewlett-Packard, Palo Alto, CA) at a resolution of 3 m and were analyzed with the GENECHIP (Affymetrix Microarray Suite 5; Affymetrix). Detailed protocols for data analysis of Affymetrix microarrays and extensive documentation of the sensitivity and quantitative aspects of the method have been described previously (Lockhart et al., 1996) . In brief, each gene is represented by the use of ϳ20 perfectly matched (PM) and mismatched (MM) control probes. The MM probes act as specificity controls that allow the direct subtraction of both background and cross-hybridization signals. The number of instances in which the PM hybridization signal is larger than the MM signal is computed, along with the average of the logarithm of the PM:MM ratio (after background subtraction) for each probe set. These values are used to make a matrix-based decision concerning the presence or absence of an RNA molecule.
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Subsequent data analysis was performed with GeneSpring analysis software (Agilent Technologies, Palo Alto, CA). Data from the Affymetrix analysis were transformed by setting measurements less than 0.01 to 0.01. Then each chip was normalized to the 50th percentile of the measurements taken from that chip. Finally, the expression of each individual gene in an experimental condition was compared with the control measurement for that gene. Changes in gene expression greater than 2-fold above or below the control (0 time) were considered significant.
Total RNA Extraction and Semiquantitative Reverse-Transcription-Polymerase Chain Reaction. Total RNA was extracted using an RNeasy total RNA isolation system (QIAGEN). RT reactions and PCR reactions were performed according to the manufacturer's protocol (SuperArray Bioscience Corporation, Frederick, MD). For amplification, the following pair of primers was used: GAPDH, sense 5Ј-TCCCATCACCATCTTCCA-3Ј and antisense 5Ј-CATCACGCCACACGAGTTTCC-3Ј; SS-A/Ro (469bp), sense 5Ј-GAACTGCTGCAGGAGGTGATAA-3Ј and antisense 5Ј-GGCACATT-CAGAGAAGGAGT-3Ј; and SS-B/La (95bp), sense 5Ј-CCAAAATCT-GTCATCAAATTGAGTATT-3Ј and antisense 5Ј-CCAGCCTTCATC-CAGTTTTATCT-3Ј. Amplification was started by heating for 1.5 min at 94°C followed by 30 cycles for 52-kDa SSA/Ro, 25 cycles for GAPDH, and 25 cycles for SSB/La, each cycle consisting of 15 s at 94°C, 30 s at 57.3°C, and 1 min at 72°C. A final extension was performed at 72°C for 5 min before gel analysis.
Western Blotting. Cells were washed in ice-cold PBS and lysed for 20 min in radioimmune precipitation buffer containing 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 10 g/ml leupeptin, 3 g/ml aprotinin, and 100 mM phenylmethylsulfonyl fluoride. Samples of lysates containing 5 to 30 g of protein (it varied in each blot against one specific antibody) were loaded in each lane and electrophoretically separated on a 12% SDS polyacrylamide gel. After electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore Corporation, Billerica, MA). The membrane was blocked for 1 h with 5% (w/v) nonfat dry milk powder in PBST and then incubated for 1 h with primary antibody diluted in PBST/milk [CENP-C, PARP, coilin, and Golgin-67 (1:500); 52-kDa Ro/SSA (1:2500); actin (1:2000); and La/SSB (1:50,000)]. The membrane was washed three times with PBST and incubated with peroxidase-conjugated affinity-purified anti-rabbit IgG (Santa Cruz Biotechnology) for 1 h. After extensive washing, the reaction was developed by enhanced chemiluminescent staining using ECL Western blotting detection reagents (GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Results
Affymetrix Gene Array Analyses. Gene arrays provide a valuable tool for studying the broad response of cells to agents, and we have used this approach to compare the differential effects of GTPP on gene expression in NHEK and OSC2 cells. The results demonstrated that approximately 2100 genes were either up-or down-regulated by at least 2-fold in response to 100 M EGCG in both cell types during the 24-h post-treatment (data not shown). Examination of the relative NHEK mRNA levels of genes represented on the gene chip encoding autoantigens previously identified in SLE (Sherer et al., 2004 ) revealed a 2-fold or greater change in expression of a number of genes during the 24-h post-treatment time course (Table 1) .
Several patterns of change were observed. For example, the nuclear autoantigen genes RNA polymerase II E and SS-B/La, a cytoskeletal autoantigen gene (␣-fodrin), and a Golgi autoantigen gene showed a general pattern of rapid (0.5-2-h initiation) decrease in mRNA levels and generally persistent 2-fold or greater reduction during the 24-h period.
Certain autoantigen genes showed an initial decrease during the first 2 h (e.g., centromere protein C1, coilin), with levels returning to near normal by 24 h. Some autoantigen genes (e.g., nuclear antigen SP100 and scleroderma autoantigen I) showed a rapid initial increase (2-4-fold) followed by a 2-fold or greater decrease. Some autoantigen genes (e.g., one of the three arrayed XRCC5/Ku autoantigen genes) showed a transient initial increase, with levels returning to near normal. In contrast, other autoantigen genes did not show a significant change during the time course of the experiment. For example, 60-kDa SS-A/Ro (SSA2) did not decline significantly (52-kDa SS-A/Ro cDNA was not included in the gene array).
Semiquantitative RT-PCR. The preliminary array analysis described above provided data suggesting that GTPP could alter the expression of some genes encoding autoantigens. To further test this possibility, three cell types, NHEK, NS-SV-AC (an SV40-immortalized cell line derived from human submandibular acinar cells), and OSC2 cells (derived from an oral squamous cell carcinoma), were treated with 100 M EGCG for different times. A semiquantitative estimate of SS-A/Ro and SS-B/La mRNA levels was then obtained by RT-PCR during the exponential period of amplification. GAPDH was used as a housekeeping gene control. SS-B/La and SS-A/Ro 52 were selected, because elevated mRNA levels (2-3-fold) of SS-A/Ro 52 and SS-B/La are found in salivary tissues of SS patients (Bolstad et al., 2003) and autoantibodies against SS-A/Ro and SS-B/La are found in nearly all (ϳ95 and 87%, respectively) primary SS patients (Hahn, 1998) . Consistent with the gene array data, SS-B/La message decreased progressively and substantially in both NHEK and NS-SV-AC cells (Fig. 1) . The levels of SS-A/Ro (52 kDa) mRNA also showed a reduction during treatment, although the effect was less pronounced than that seen for SS-B/La and was not prominent until 24 h. In OSC2 cells, the reduction in SS-B/La mRNA was less pronounced and did not occur until 24 h of exposure, whereas SS-A/Ro mRNA showed little change. GAPDH also showed no marked decrease in these cells in response to EGCG, indicating that the reduction in mRNA levels seen for SS-B/La and SS-A/Ro was not due to a generalized effect on the cells.
Western Blotting. To extend the mRNA data, the protein levels of six different autoantigens in NHEK and NS-SV-AC cells were determined by Western analysis after two treatments with 100 M EGCG at 24 and then 48 h. As shown in Fig. 2 , coilin and PARP protein levels were significantly reduced in both cell lines by 24 h and were barely detectable after 48 h. CENP-C showed a similar trend, although the reduction was less pronounced. Neither SS-A/Ro 52 nor SS-B/La was dramatically reduced in either cell line by 24 h but was considerably reduced by 48 h. Golgin-67 was reduced in NS-SV-AC cells by 24 h and barely detectable at 48 h. Golgin-67 was also reduced in NHEK cells, although the reduction was not as marked and was only observed at 48 h. Actin protein levels were unchanged by EGCG during the 48-h treatment period.
Discussion
Studies over the past 20 years have demonstrated that GTPP possess chemoprevention activities and antioxidant, anti-inflammatory, and antiapoptotic properties (Sueoka et al., 2001) , suggesting that they could be beneficial to patients with auto- The following autoantigens  were not detected: ABCA7, AMPH, ANXA11, ASRGL1, CENPE, CHD3, CHD5, DEAF1, FLJ10613, FLJ12595, GAD1, GAD2, GMEB1, GOLGA6, ICA1, LMOD1, LOC93349,  PC, PRTN3, PTPRN, PTPRN2, RCD-8, SC65, SE20 -4, SP140, SSA1, STRN, TIGD6, TMPRSS3, immune disorders. Green tea consumption has been shown to have protective effects in autoimmune animal models (Yang et al., 1998; Haqqi et al., 1999; Sayama et al., 2003; Roca et al., 2004) . There are several mechanisms by which green tea could act. Apoptosis has been implicated in the presentation of autoantigens and tissue destruction in autoimmune disorders, and reduction in this event could ameliorate symptoms. GTPP have been shown to induce differential responses in normal versus tumor cells. Normal cells are protected; e.g., EGCG protects human salivary acinar and duct cells from radiation and chemotherapeutic drug-induced apoptosis (Yamamoto et al., 2004) and induced terminal differentiation in NHEK . In contrast, tumor cells are induced to undergo apoptosis (Ahmad et al., 1997 . GTPP potently inhibited TNF-␣, a proapoptotic cytokine (Yang et al., 1998) , and EGCG inhibited TNF-␣-mediated activation of the NF-B pathway, thereby protecting normal cells from TNF-␣-induced apoptosis (Wheeler et al., 2004) . Autoimmune disorders have an inflammatory component. Recently, the anti-inflammatory effects of green tea have been explored with promising results (reviewed in Curtis et al., 2004) . Studies using transgenic mice suggest that one way in which green tea may block diseases associated with cytokine overexpression is by inhibiting transcription of the proinflammatory cytokines TNF-␣ and IL-6 (Sueoka et al., 2001) . EGCG also showed inhibitory effects on inflammatory pathways mediated by the inflammatory cytokine IL-1 (Wheeler et al., 2004) and effectively inhibited IL-1␤-induction of matrix metalloproteinases 1 and 13 (Ahmed et al., 2004) . The inhibition of IL-1␤ signaling may occur through the modulation of the mitogen-activated protein kinase pathway components . Green tea and EGCG are able to inhibit IL-8 release in TNF-␣-stimulated NHEK Inhibition of Autoantigens by EGCG (Trompezinski et al., 2003) . A recent study showed that EGCG suppressed lipopolysaccharide-induced dendritic cell maturation, therefore reducing the subsequent T cell activation (Ahn et al., 2004) . A significant number of autoantibodies have been described for SLE (Sherer et al., 2004) , and there is overlap with the autoantibodies found in the sera of patients with SS. The mechanisms leading to presentation of autoantigens to the immune system are not fully understood. One mechanism may be the translocation of nuclear autoantigens onto the cell membrane during apoptosis, where they are exposed to antigen-presenting cells (Manganelli and Fietta, 2003) . During apoptosis, autoantigens redistribute to form apoptotic bodies and blebs, where autoantigens such as SS-A/Ro, SS-B/La, Ku, PARP, fodrin, golgins, and nuclear mitotic apparatus protein (NuMA) are clustered as subcellular structures. An aberrant structure of these autoantigen complexes may contribute to the autoimmune response (Rosen and Casciola-Rosen, 2004) . B cells can be stimulated to proliferate and produce autoantibodies by perturbations in the levels of cytokines. Although the exact role of autoantibodies in the pathogenesis of SLE or SS remains unclear, it is thought that they are involved directly in some of the clinical manifestations (Mamula et al., 1994) .
Inhibition of Autoantigens by EGCG
Herein, we report the novel finding that EGCG, the most abundant GTPP, down-regulates the expression of different autoantigens at the mRNA and/or protein levels in different epithelial cell types. This represents a third mechanism, in addition to reducing apoptosis and inflammation, by which GTPP could be useful to the prevention of and intervention in autoimmune disorders. The concentration of EGCG used in this study (100 M) is achievable in the salivary glands (Yang et al., 1999) and topically if the skin barrier is interrupted, as among the patients with SLE and psoriasis.
Results from the Affymetrix gene expression analyses indicated that EGCG modulated the expression of a group of major autoantigens in NHEK, with several genes showing a 2-fold or more reduction in mRNA levels, in some cases after an initial increase. The various different patterns in the kinetics of change among different autoantigens suggest that different regulatory mechanisms could be involved. A reduction in expression of SS-B/La and SS-A/Ro in NHEK and NS-SV-AC cells over a 24-h period was confirmed by RT-PCR (Fig. 1) . In OSC2 cells, the effects of EGCG were less pronounced. This difference is consistent with the different response of this cell line toward EGCG (apoptosis instead of differentiation) and suggests that the pathways mediating the inhibitory effect of EGCG on autoantigen expression are altered in tumor cells. It is known that GTPP induces terminal differentiation in NHEK , raising the possibility that the decrease in expression seen in these cells is a consequence of this induction. However, because NS-SV-AC cells are immortalized human salivary acinar cells derived from fully differentiated acinar cells, the down-regulation of autoantigens is not necessarily associated directly with cell differentiation.
The SS-A/Ro autoantigen represents at least two independently expressed nucleocytoplasmic ribonucleoproteins, 60-kDa SS-A/Ro and 52-kDa SS-A/Ro, which complex noncovalently with small RNA species Y1 to Y5 (Chan et al., 1990) . In patients with SS and SLE, 52-kDa SS-A/Ro is the main epitope recognized by anti-SS-A/Ro autoantibodies (Kubo et al., 2002) . Elevated mRNA levels (2-3-fold) of SS-A/Ro 52 and SS-B/La are found in salivary tissues of SS patients (Bolstad et al., 2003) , and autoantibodies against SS-A/Ro and SS-B/La are found in nearly all (ϳ95 and 87%, respectively) primary SS patients (Hahn, 1998) . During apoptosis, both SS-A/Ro and SS-B/La translocate from the nucleus to the membrane, which may present them as targets for ANA (McArthur et al., 2002) . Expression of SS-A/Ro 52 (which was not represented on the Affymetrix array) was shown to be reduced by EGCG at the mRNA and protein level in two different epithelial cell lines using RT-PCR and Western analyses. Likewise, microarray, RT-PCR, and Western analyses demonstrated that EGCG reduced expression of SS-B/ La. In contrast, the microarray analysis showed that SS-A/Ro 60 mRNA levels were not significantly altered by EGCG. It is noteworthy that oxidative stress induces cell surface expression of SS-A/Ro 52 but not SS-A/Ro 60 autoantigen on NHEK cells (Saegusa et al., 2002) . Because GTPP inhibit the effects of oxidative stress on normal cells (Yamamoto et al., 2004) , this may be one mechanism by which EGCG reduces expression of autoantigens. An inhibitory effect of EGCG on protein levels of four other autoantigens was demonstrated by Western analysis in NHEK and NS-SV-AC cells. The kinetics of reduction in protein levels differed somewhat between the 
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autoantigens. This could reflect regulation via different pathways or differences in mRNA or protein stability or in protein trafficking.
In conclusion, here we report for the first time that the most abundant green tea constituent, EGCG, specifically inhibits expression of certain major autoantigens at the mRNA and protein level in NHEK and human salivary acinar cells, two cell types often damaged by SLE and SS, respectively. Our results suggest that EGCG may be able to modulate the presentation of autoantigens, thereby potentially reducing the targets of autoimmune reactions. Most current approaches to treating SLE and SS focus on modifying the immune response (Goldblatt and Isenberg, 2005) . We hypothesize that oral/topical administration of GTPP might delay the onset and reduce the severity of autoimmune disorders by 1) reducing autoimmune responses and decreasing the generation of autoantibodies via inhibition of autoantigen expression, 2) protecting the targeted cells, such as epidermal keratinocytes and glandular secretory cells, from apoptosis, leading to reduced membrane autoantigen presentation, and 3) inhibiting inflammation in affected tissues. Future studies in animal models and clinical trials will be needed to develop novel approaches for the prevention and treatment of autoimmune disorders using active phytochemicals such as EGCG.
